Just 66% of person-years in whom targeted therapies were indicated in 2020 and 2021 were associated with use of those medications, suggesting that at least 500 Medicaid patients with a diagnosis of EGFR- or ALK-altered metastatic NSCLC during these years did not receive targeted therapy when indicated. This evidence concerns the gene ALK and non-small cell lung carcinoma.